microdosing semaglutide results Woman shares what happened after she stopped taking Microdosing GLP-1's for Weight Loss

Expect some GI adjustment but potentially less severe than a completely naive start

1 ,2 About the REDEFINE 1 trial REDEFINE 1 was a double-blind, placebo-and active-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg), cagrilintide 2.4 mg monotherapy and semaglutide 2.4 mg monotherapy versus placebo in 3,417 adults with obesity (BMI 30 kg/m 2 ), or overweight (BMI 27 kg/m 2 ) with one or more obesity-related comorbidities, and without type 2 diabetes

For most people, nausea is a short-term challenge

1 For the individual MACE components, there were significantly lower and quantitatively similar hazard ratios for nonfatal stroke and CVD mortality, but the hazard ratio for nonfatal myocardial infarction was nonsignificant

Our doctor-led approach uses proven GLP-1 medications and personalized care to help you succeed where other methods have failed

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)